A minority of patients in the The Cancer Genome Atlas GBM dataset had MYC, MYCN, or CDK18 amplifications or altered mRNA levels, and there was no overlap between amplification of CDK18 and MYC or MYCN, suggesting a negative association of CDK18 and MYC or MYCN (Supplementary Fig. 4). This evidence concerns the gene MYCN and glioblastoma.